Our aim in the current study of 20 normal controls, 28 overweight, and 26 severely overweight (obese) subjects was to assess interrelationships of obesity, endogenous estradiol (E2) and testosterone (T), and the E2/T ratio with major independent explanatory variables for coronary heart disease (CHD), including lipids, lipoproteins, and apolipoproteins. Most of the lipid and lipoprotein variables (total, high-, low-, and very-low-density lipoprotein cholesterols) as well as apolipoproteins A1, A2, and B did not vary significantly with the presence of obesity. With increasing relative ponderosity, there were, however, increasing levels of total triglycerides and VLDL triglyceride. Levels of FSH, LH, prolactin, and testosterone did not differ significantly with obesity. The obese subjects had the highest E2 and E2/T levels; overweight subjects had intermediate levels which were also significantly higher than in the controls. Using multiple regression analyses, in obese subjects increasing T was associated with increasing apo B, and increasing E2 was correlated with decreasing apo A1. Opposite relationships were found in the normal controls where increasing T and increasing Quetelet indices were associated with diminished apo B and increasing E2 was associated with increasing A1. Obesity's association with increased CHD risk may be mediated through increasing E2 and apo B and reducing apo A1. Since obese subjects have higher E2 levels and often have lower T, they are likely to have a pattern of endogenous sex hormones (higher E2, lower T, higher E2/T ratios) similar to those observed in young men with premature myocardial infarction.

Download full-text PDF

Source

Publication Analysis

Top Keywords

obese subjects
20
increasing
10
sex hormones
8
lipoprotein cholesterols
8
normal controls
8
increasing associated
8
associated increasing
8
increasing apo
8
apo increasing
8
subjects
6

Similar Publications

Aortic dissection is a life-threatening vascular emergency associated with high morbidity and mortality. Clinical manifestations might include severe chest pain to neurological deficits, depending on the arterial segments involved. Extensive dissections involving multiple aortic segments and branch vessel occlusions, such as the carotid arteries, are rare and pose unique diagnostic and therapeutic challenges.

View Article and Find Full Text PDF

Background The escalating global obesity epidemic requires comprehensive investigations for effective weight management strategies. Understanding the patterns, barriers, and facilitators of dietary interventions is crucial for developing effective weight management protocols. This research aims to assess dietary modification interventions among weight loss subjects in Tamilnadu, South India.

View Article and Find Full Text PDF

Exploring serum miR-33b as a novel diagnostic marker for hypercholesterolemia and obesity: insights from a pilot case-control study.

BMC Endocr Disord

January 2025

Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, of Clinical Biochemistry, Kerman University of Medical Sciences, Jahad Boulevard Avicenna Avenue, Kerman, 7619813159, Iran.

Obesity and atherosclerosis are significant metabolic diseases characterized by disrupted lipid metabolism. MicroRNAs (miRNAs) are small, conserved, non-coding RNA sequences consisting of approximately 22 nucleotides, playing crucial roles in biological and pathological functions. Among these, miR-33a/b is particularly associated with metabolic diseases, notably obesity and atherosclerosis.

View Article and Find Full Text PDF

Background: The relationship between body roundness index (BRI), a new obesity index, and frailty has not been established. This study aims to compare the associations of traditional obesity index body mass index (BMI) and BRI with frailty and the risk of all-cause mortality.

Methods: The clinical data of 15,157 participants over 40 years old from the National Health and Nutrition Examination Survey (NHANES) from 2003 to 2018 were analyzed.

View Article and Find Full Text PDF

AimsThe cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!